---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-019911"
form_type: "8-K"
ticker: "ACRS"
cik: "0001557746"
company_name: "Aclaris Therapeutics, Inc."
filed_at: "2023-12-19T23:59:59+00:00"
generated_at: "2026-06-07T10:32:33.728448+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aclaris cuts workforce 46%, expects ATI-1777 Phase 2b topline data in Jan 2024

## Summary
- Workforce reduction of ~46%; one-time charge ~$3.1M in Q4 2023, total costs $5.0-5.3M over 12 months.
- ATI-1777 Phase 2a results published in JID Innovations; Phase 2b topline data expected January 2024.
- ATI-450 (zunsemetinib) repurposed for pancreatic cancer and metastatic breast cancer in collaboration with Washington University.
- ATI-2138 (ITK/JAK3) indication reassessed due to competitive landscape; guidance in early 2024.
- Company accelerating discovery programs from KINect platform to generate IND applications near term.

## SEC filing metadata
- accession: 0001558370-23-019911
- form_type: 8-K
- ticker: ACRS
- cik: 0001557746
- company_name: Aclaris Therapeutics, Inc.
- filed_at: 2023-12-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.05, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557746/000155837023019911/0001558370-23-019911-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557746/000155837023019911/acrs-20231219x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-019911
- JSON: https://secwatch.observer/filing/0001558370-23-019911.json
- Plain text: https://secwatch.observer/filing/0001558370-23-019911.txt

## Key facts
- Restructurings & Charges
  Aclaris Therapeutics, Inc. announced a restructuring with charges of totaling approximately $3.1 million (approximately 46%).
  - Type: restructuring
  - Charge: totaling approximately $3.1 million
  - Headcount: approximately 46%
  source text: order to streamline operations, reduce costs and preserve capital. ​ As a result of the reduction in force, the Company expects to incur a one-time charge totaling approximately $3.1 million in connection with one-time employee termination costs, including severance and other benefits. This charge is expected to be incurred during the quarter ending December 31,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1557746/000155837023019911/0001558370-23-019911-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.